Navigation Links
Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Date:6/4/2008

MOORESVILLE, N.C., June 4 /PRNewswire-FirstCall/ -- Anpath Group, Inc. (OTC Bulletin Board: ANPG), reported today that its wholly owned subsidiary, EnviroSystems, Inc. (ESI) announced that the U.S. Environmental Protection Agency (EPA) accepted its submission to add additional claims to its disinfectant/sanitizer, EnviroTru(R) for use of the product as a sanitizer against the "superbug" MRSA (scientifically known as Methicillin Resistant Staphylococcus aureus) and VRE (scientifically known as Vancomycin Resistant Enterococcus faecalis). Having received approval from the federal EPA for these additional claims, the company has commenced the state registration process which it believes should be completed with the majority of states within 30 days.

EnviroTru(R) ( http://www.envirosi.com/products/envirotru.htm ) is a multi-purpose disinfectant, sanitizer and deodorizing cleaner, effective against numerous organisms, and also meets EPA requirements for Toxicity Category IV (no harmful dermal, ocular, inhalation or ingestion effects). EnviroTru(R) does not require protective clothing, gloves or special ventilation and has passed the AMS 1452A, AMS 1453 and Boeing D6-7127 specifications for non-corrosion and materials compatibility.

J. Lloyd Breedlove, President and CEO of Anpath Group, stated, "We are confident these additional claims will add to the growing market demand for EnviroTru(R). The timeliness of this registration is noteworthy considering the increased incidence of MRSA cases reported in public settings; particularly schools." Mr. Breedlove continued, "These claims are a small part of our aggressive development and testing program intended to expand our product offering. Moreover, while the ability to kill potentially harmful microorganisms is important, it is just as important that the biocide have a favorable profile for health and environmental effects. It is not acceptable to trade one problem for another by using potentially harmful chemicals to clean and disinfect. ESI has a single goal - reduce biological risks by destroying a wide range of disease-causing microorganisms with minimum risk to our customer, surfaces and the environment."

Methicillin Resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA is a resistant variation of the common bacterium Staphylococcus aureus. It has evolved an ability to survive treatment with beta-lactam antibiotics, including penicillin, methicillin, and cephalosporins. MRSA was discovered in 1961 in the UK and it is now found worldwide, and is often referred to in the press as a "superbug". In the past decade or so the number of MRSA infections in the United States has increased significantly. At the same time, a growing number of cases were noted in schools around the nation, with many closing their doors to scrub down their facilities. After the death of a 17-year-old Virginia student, the school district closed all 21 schools for cleaning. A 2007 report in Emerging Infectious Diseases, a publication of the Centers for Disease Control and Prevention (CDC), estimated that the number of MRSA infections treated doubled nationwide, from approximately 127,000 in 1999 to 278,000 in 2005, while at the same time deaths increased from 11,000 to more than 17,000. Another study led by the CDC and published in the October 17, 2007 issue of the Journal of the American Medical Association estimated that MRSA would have been responsible for 94,360 serious infections and associated with 18,650 hospital stay-related deaths in the United States in 2005. These figures suggest that MRSA infections are responsible for more deaths in the U.S. each year than AIDS.

Enterococci are bacteria that are normally present in the human intestines and in the urinary tract and are often found in the environment. These bacteria can sometimes cause infections. Vancomycin is an antibiotic that is often used to treat infections caused by Enterococci. In some instances, Enterococci have become resistant to this drug and thus are called Vancomycin Resistant Enterococci faecalis (VRE).

About Anpath Group, Incorporated:

Anpath Group, Inc., through its wholly owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment. Visit http://www.anpathgroup.com for more information.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks - both natural and man-made.

Forward Looking Statements:

This release contains forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA registration of the Company's products, the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no duty to update its outlook or other forward-looking statements as of any future date.


'/>"/>
SOURCE Anpath Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
2. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
3. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Wound Management Technologies, Inc. Announces Evidence Based Study
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
8. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
11. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ... announced a new partnership to reach nearly 1 million children with important water safety ... and is the leading cause of accidental death in children one to 6 years ...
(Date:5/5/2016)... ... May 05, 2016 , ... In ... every day living patterns, Amerec, a Seattle-based steam bath and sauna manufacturer recently ... , The user interface of the app, developed for both smartphones and personal ...
(Date:5/5/2016)... York) , ... (PRWEB) May 05, 2016 , ... ... talent acquisition startup, HireNurses, on the eve of National Nurses Week (May ... nurses and healthcare employers. With their enrollment into the Talent Tech Lab Virtual Incubation ...
(Date:5/5/2016)... MA (PRWEB) , ... May 05, 2016 , ... Chronic ... becomes a constant presence, it can weaken the immune system and increase inflammation, both ... B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts General ...
Breaking Medicine News(10 mins):